Display options
Cite
Saito R, Terasaki N, Yamazaki M, et al. Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells. J Toxicol. 2016;2016:4041827doi: 10.1155/2016/4041827.
Saito, R., Terasaki, N., Yamazaki, M., Masutomi, N., Tsutsui, N., & Okamoto, M. (2016). Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells. Journal of toxicology, 20164041827. https://doi.org/10.1155/2016/4041827
Saito, Ryuta, et al. "Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells." Journal of toxicology vol. 2016 (2016): 4041827. doi: https://doi.org/10.1155/2016/4041827
Saito R, Terasaki N, Yamazaki M, Masutomi N, Tsutsui N, Okamoto M. Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells. J Toxicol. 2016;2016:4041827. doi: 10.1155/2016/4041827. Epub 2016 Feb 17. PMID: 27057163; PMCID: PMC4773560.
Copy Download .nbib Format: NLM
Share it on

J Toxicol. 2016;2016:4041827. doi: 10.1155/2016/4041827. Epub 2016 Feb 17.

Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells.

Journal of toxicology

Ryuta Saito, Natsuko Terasaki, Makoto Yamazaki, Naoya Masutomi, Naohisa Tsutsui, Masahiro Okamoto

Affiliations

  1. Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan; Biology Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan; DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan.
  2. Safety Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Kisarazu-shi, Chiba 292-0818, Japan.
  3. DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan.
  4. Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan.

PMID: 27057163 PMCID: PMC4773560 DOI: 10.1155/2016/4041827

Abstract

Adrenal toxicity is one of the major concerns in drug development. To quantitatively understand the effect of endocrine-active compounds on adrenal steroidogenesis and to assess the human adrenal toxicity of novel pharmaceutical drugs, we developed a mathematical model of steroidogenesis in human adrenocortical carcinoma NCI-H295R cells. The model includes cellular proliferation, intracellular cholesterol translocation, diffusional transport of steroids, and metabolic pathways of adrenal steroidogenesis, which serially involve steroidogenic proteins and enzymes such as StAR, CYP11A1, CYP17A1, HSD3B2, CYP21A2, CYP11B1, CYP11B2, HSD17B3, and CYP19A1. It was reconstructed in an experimental dynamics of cholesterol and 14 steroids from an in vitro steroidogenesis assay using NCI-H295R cells. Results of dynamic sensitivity analysis suggested that HSD3B2 plays the most important role in the metabolic balance of adrenal steroidogenesis. Based on differential metabolic profiling of 12 steroid hormones and 11 adrenal toxic compounds, we could estimate which steroidogenic enzymes were affected in this mathematical model. In terms of adrenal steroidogenic inhibitors, the predicted action sites were approximately matched to reported target enzymes. Thus, our computer-aided system based on systems biological approach may be useful to understand the mechanism of action of endocrine-active compounds and to assess the human adrenal toxicity of novel pharmaceutical drugs.

References

  1. Toxicol Pathol. 2001 Jan-Feb;29(1):41-8 - PubMed
  2. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305 - PubMed
  3. Cancer Res. 1990 Sep 1;50(17):5488-96 - PubMed
  4. Nat Med. 2010 Jan;16(1):67-74 - PubMed
  5. Toxicol Pathol. 1989;17(2):317-29 - PubMed
  6. J Cardiovasc Pharmacol. 2006 Jan;47(1):133-8 - PubMed
  7. Mol Cell Endocrinol. 1979 Mar;13(3):213-27 - PubMed
  8. J Appl Toxicol. 2007 Mar-Apr;27(2):103-15 - PubMed
  9. J Steroid Biochem Mol Biol. 1997 Feb;60(3-4):189-95 - PubMed
  10. Endocrinology. 1986 Mar;118(3):1229-32 - PubMed
  11. Steroids. 1971 May;17(5):559-74 - PubMed
  12. Res Commun Chem Pathol Pharmacol. 1988 Jul;61(1):27-34 - PubMed
  13. J Steroid Biochem Mol Biol. 2002 Mar;80(3):355-63 - PubMed
  14. Endocrinology. 2012 Sep;153(9):4354-66 - PubMed
  15. Prog Biophys Mol Biol. 2006 Jan-Apr;90(1-3):360-77 - PubMed
  16. Steroids. 2014 Jun;84:103-10 - PubMed
  17. Fertil Steril. 1988 Jan;49(1):62-5 - PubMed
  18. Reprod Biol Endocrinol. 2013 Feb 19;11:9 - PubMed
  19. Pharmacotherapy. 1981 Sep-Oct;1(2):95-120 - PubMed
  20. Endocr J. 2013;60(3):329-36 - PubMed
  21. Toxicol Pathol. 1999 Sep-Oct;27(5):563-72 - PubMed
  22. Horm Metab Res. 2009 Jan;41(1):35-9 - PubMed
  23. Am J Hypertens. 2015 Jan;28(1):113-20 - PubMed
  24. J Pharmacol Toxicol Methods. 1994 Sep;32(1):1-6 - PubMed
  25. J Steroid Biochem. 1989 Apr;32(4):515-24 - PubMed
  26. J Med Chem. 2012 Jul 26;55(14 ):6629-33 - PubMed
  27. Toxicol Sci. 2011 Sep;123(1):80-93 - PubMed
  28. J Clin Endocrinol Metab. 2014 Feb;99(2):E257-62 - PubMed
  29. Acta Endocrinol (Copenh). 1975 Nov;80(3):517-26 - PubMed
  30. J Biol Chem. 1986 Mar 15;261(8):3556-62 - PubMed
  31. Math Biosci. 2008 Sep;215(1):105-14 - PubMed
  32. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):259-70 - PubMed
  33. J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):229-36 - PubMed
  34. Biochim Biophys Acta. 2007 Jun;1771(6):663-76 - PubMed
  35. Toxicol Appl Pharmacol. 2006 Oct 15;216(2):274-81 - PubMed
  36. Toxicology. 2001 Aug 28;165(2-3):171-8 - PubMed
  37. Mol Cell Endocrinol. 2007 Feb;265-266:42-5 - PubMed
  38. Bioinformatics. 2003 Mar 22;19(5):643-50 - PubMed
  39. Arch Pharm (Weinheim). 2004 Jul;337(7):411-6 - PubMed
  40. J Clin Endocrinol Metab. 1993 Sep;77(3):731-7 - PubMed
  41. Toxicol Sci. 2004 Sep;81(1):78-89 - PubMed
  42. Mol Cell Endocrinol. 2015 Jun 15;408:107-13 - PubMed
  43. Clin Endocrinol (Oxf). 1991 Aug;35(2):163-8 - PubMed
  44. Toxicol In Vitro. 2012 Mar;26(2):343-50 - PubMed
  45. Am J Physiol. 1984 Apr;246(4 Pt 2):R587-96 - PubMed
  46. J Pharmacol Exp Ther. 1987 Jan;240(1):259-64 - PubMed
  47. Amino Acids. 2010 Jan;38(1):179-87 - PubMed
  48. Environ Sci Technol. 2009 May 15;43(10):3926-32 - PubMed
  49. Metabolism. 1994 Jun;43(6):723-7 - PubMed
  50. Curr Hypertens Rep. 2011 Apr;13(2):103-8 - PubMed
  51. Nihon Naibunpi Gakkai Zasshi. 1985 Mar 20;61(3):168-78 - PubMed
  52. J Comp Physiol B. 2001 Aug;171(6):519-26 - PubMed
  53. Toxicol In Vitro. 2002 Apr;16(2):113-21 - PubMed
  54. Mol Cell Endocrinol. 2015 Jun 15;408:205-12 - PubMed
  55. Res Commun Chem Pathol Pharmacol. 1988 Jul;61(1):17-26 - PubMed
  56. Fundam Appl Toxicol. 1984 Feb;4(1):105-19 - PubMed
  57. Mol Endocrinol. 1993 Mar;7(3):423-33 - PubMed
  58. Environ Health Perspect. 2010 Feb;118(2):265-72 - PubMed
  59. Mol Pharmacol. 1991 Aug;40(2):321-5 - PubMed
  60. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92 - PubMed
  61. Toxicology. 2004 Feb 15;195(2-3):177-86 - PubMed
  62. J Appl Toxicol. 2003 Mar-Apr;23(2):81-7 - PubMed
  63. Biochim Biophys Acta. 2000 Dec 15;1529(1-3):175-87 - PubMed
  64. J Clin Endocrinol Metab. 1984 Jul;59(1):51-5 - PubMed
  65. Toxicol Appl Pharmacol. 2006 Nov 15;217(1):114-24 - PubMed
  66. Bioprocess Biosyst Eng. 2004 Oct;26(5):295-306 - PubMed
  67. Endocrinology. 1976 Oct;99(4):1097-106 - PubMed
  68. Exp Biol Med (Maywood). 2009 Aug;234(8):880-907 - PubMed
  69. Endocr Rev. 1996 Jun;17(3):221-44 - PubMed
  70. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4415-21 - PubMed
  71. Clin Cardiol. 2008 Apr;31(4):153-8 - PubMed

Publication Types